> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Enterocolitis after BCMA-directed CAR T cell therapy resolved in about a third of patients
- URL: https://www.coios.me/enterocolitis-after-bcma-directed-car-t-cell-therapy/
- Published: 2026-11-21T13:02:19.000Z
- Updated: 2026-11-21T16:37:22.000Z
- Description: Enterocolitis after BCMA-directed CAR T cell therapy resolved by last follow-up in 32% of patients, with some deaths from complications.
- Author: Daniel Ryan
- Tags: Tomorrow's world, Innovation in treatment, #peer-reviewed, #new, #item, #source-2026-11, #score-62

The study described immune effector cell-associated enterocolitis, a gut inflammation seen after BCMA-directed CAR T cell therapy. It was a large case series of patients who developed the disorder across several treatment centres. Only 32% of patients had achieved resolution of the enterocolitis at last follow-up. Some deaths were directly attributed to complications of the disorder. As a case series it has no comparison group or incidence rate. Patient numbers and follow-up length are not reported.

*Why it is interesting: BCMA-directed CAR T cell therapy is a recent form of treatment. In this series the related gut disorder was mostly unresolved at last follow-up, and some deaths followed from its complications.*

Source

[Nature Medicine, 19 November 2026](https://www.nature.com/articles/s41591-026-04783-y?ref=coios.me)

Type

Peer-reviewed article

Design

Multicentre retrospective case series of immune effector cell-associated enterocolitis after BCMA-directed CAR T therapy; n and years not stated in abstract

Verdict

New finding

Driver

[Innovation in treatment](https://www.coios.me/d-treatment-innovation/)